Carrier screening and prenatal diagnosis for thalassemia-associated mutations in Jiaxing area of Zhejiang.
10.3760/cma.j.cn511374-20220121-00054
- Author:
Huling JIANG
1
;
Chiyan ZHOU
;
Li YANG
;
Suping LI
;
Xiaodan LIU
Author Information
1. Prenatal Diagnosis Center, Jiaxing Maternity and Child Health Care Hospital, Jiaxing, Zhejiang 314009, China. 80liuxiaodan@163.com.
- Publication Type:Journal Article
- MeSH:
Female;
Humans;
Pregnancy;
Electrophoresis, Capillary;
Genetic Counseling;
Genetic Testing;
Mutation;
Prenatal Diagnosis;
Thalassemia/genetics*
- From:
Chinese Journal of Medical Genetics
2023;40(3):295-300
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the molecular epidemiology of thalassemia in Jiaxing area of Zhejiang province and provide a basis for prenatal diagnosis, genetic counseling and prevention and control of birth defects.
METHODS:A total of 24 003 pregnant women who presented at the Jiaxing Maternal and Child Health Care Hospital from April 2017 to September 2021 were enrolled. Capillary hemoglobin electrophoresis in combination with routine blood test were used for primary screening for carriers of thalassemia-associated mutations, and those with positive results were subjected to fluorescence quantitative PCR assay. Prenatal diagnosis was provided for couples with a risk of giving birth to children with intermediate or severe thalassemia.
RESULTS:Among the 24 003 pregnant women, 1 211 cases were suspected as carriers of thalassemia-associated mutations, among whom 443 (36.58%) were confirmed by genetic testing. Among these, carriers of α-, β- and α-complex β-globin gene mutations have accounted for 27.31% (121/443), 70.65% (313/443) and 2.04% (9/443), respectively. The result of prenatal diagnosis for an at-risk couple was --SEA/αCSα, and the fetus was predicted to have intermediate or severe thalassemia. Termination of the pregnancy was recommended.
CONCLUSION:Hemoglobin electrophoresis combined with routine blood test during pregnancy may be used as a preliminary screening measure for carriers of thalassemia-associated variants. Combined with genetic testing, this will be of great significance for the control of thalassemia in this region.
